This study is looking at the eye-related side effects of Tivdak®, a medicine used to treat cervical cancer that has returned or spread after chemotherapy (a treatment using medicines to stop cancer cell growth). You may be able to join if you are an adult woman with recurrent or metastatic cervical cancer, and your doctor believes Tivdak® is a suitable treatment for you. You should not have received Tivdak® before and should not have active eye problems. The study aims to understand the types, frequency, and severity of eye side effects up to 90 days after your last dose of Tivdak®. About 100 participants are planned for this study.

Study design

This is an interventional study planning to enroll 100 participants. It focuses on understanding side effects of Tivdak®.

What's involved

You will receive Tivdak® as an infusion into your vein once every 3 weeks. You must be willing to take all required eye tests.

Compensation

Not stated in the trial record.

Follow-up

Your eye side effects will be measured for 90 days after your last dose of Tivdak®.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.